Efficacy of bevacizumab against interface neovascularization after deep anterior lamellar keratoplasty

Cornea

Volumn 31, Issue 2, 2012, Pages 188-190

  Jarrín, Elena ^a   Ruiz Casas, Diego ^a   Mendivil, Antonio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

bevacizumab; herpetic keratopathy; lamellar keratoplasty; neovascularization

Indexed keywords

BEVACIZUMAB; CREATININE; VALACICLOVIR;

ARTICLE; BLOOD CELL; BLUNT TRAUMA; CASE REPORT; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CREATININE BLOOD LEVEL; DEEP LAMELLAR ENDOTHELIAL KERATOPLASTY; EYE INJURY; HERPES SIMPLEX KERATITIS; HUMAN; INTRAOCULAR PRESSURE; MALE; PHACOEMULSIFICATION; PRIORITY JOURNAL; SURGICAL APPROACH; VIRUS REACTIVATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; HUMANS; KERATITIS; MALE; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 84855836193     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31820ca19e     Document Type: Article

References (24)

1. Gerten G. Bevacizumab (Avastin) and argon laser to treat neovasculariza-tion in corneal transplant surgery. Cornea. 2008;27:1195-1199.
2. Harooni H, Reddy V, Root T, et al. Bevacizumab for graft rejection. Ophthalmology. 2007;114:1950.
3. Awadein A. Subconjunctival bevacizumab for vascularised rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993. (Pubitemid 47615364)
4. Shtein RM, Garcia DD, Musch DC, et al. Herpes simplex virus keratitis: histopathologic inflammation and corneal allograft rejection. Ophthalmology. 2009;116:1301-1305.
5. Lee E, Mavrikakis I, Paul B, et al. Intralamellar haemorrhage 44 years following lamellar keratoplasty. Eye. 2006;20:967-968. (Pubitemid 44210208)
6. Miserocchi E, Modorati G, Galli L, et al. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. Am J Ophthalmol. 2007;144:547-551.
7. Godblum D, Bachmann C, Tappeiner C, et al. Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis. Ophthalmology. 2008;92:1201-1205.
8. Soong HK, Katz DJ, Farjo AA, et al. Central lamellar keratoplasty for optical indications. Cornea. 1999;18:249-256. (Pubitemid 29205546)
9. Huang T, Planck SR, Rosenbaum JT, et al. Feasibility study of lamellar keratoplasty in a murine model. Ocul Immunol Inflamm. 2009;17: 257-264.
10. Amano S, Rohan R. Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascula-rization. Invest Ophthalmol Vis Sci. 1998;39:18-22. (Pubitemid 28040457)
11. Zheng M, Deshpande S, Lee S, et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol. 2001;75:9828-9835. (Pubitemid 32900118)
12. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249. (Pubitemid 32751680)
13. Reinhard T, Reis A, Bohringer D, et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol. 2001;239:367-372. (Pubitemid 32600194)
14. Bienbaum F, Reis A, Reinhard T. Topical immunosuppressives after penetrating keratoplasty. Ophthalmologe. 2007;104:381-387.
15. Bienbaum F, Bohringer D, Sokolaska Y, et al. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation. 2005;79:964-968. (Pubitemid 40586871)
16. Joussen AM, Germann T, Kirchhof B. Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency. Graefes Arch Clin Exp Ophthalmol. 1999;237: 952-961. (Pubitemid 30021284)
17. Ostler HB. Glucocorticoid therapy in ocular herpes simplex I. Limitations. Surv Ophthalmol. 1978;23:35-43.
18. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ. 2010;340:c2459.
19. Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008;126: 1161-1163.
20. Chang LK; Spaide RF, Brue C, et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol. 2008;126:941-945. (Pubitemid 352008374)
21. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147. (Pubitemid 351158729)
22. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab in corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
23. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009;127:381-389.
24. Carrasco MA. Subconjunctival bevacizumab for corneal neovasculariza-tion in herpetic stromal keratitis. Cornea. 2008;27:743-745.